Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasterideMÜNSTER, U; HAMMER, S; BLUME-PEYTAVI, U et al.Skin pharmacology and applied skin physiology. 2003, Vol 16, Num 6, pp 356-366, issn 1422-2868, 11 p.Article

Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in thetreatment of benign prostatic hyperplasiaANDRIOLE, Gerald L; KIRBY, Roger.European urology. 2003, Vol 44, Num 1, pp 82-88, issn 0302-2838, 7 p.Article

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III studyHEE CHUL EUN; OH SANG KWON; HWA YOUNG PARK et al.Journal of the American Academy of Dermatology. 2010, Vol 63, Num 2, pp 252-258, issn 0190-9622, 7 p.Article

Effect of dutasteride therapy on doppler US evaluation of prostate : Preliminary resultsIVES, Elizabeth P; GOMELLA, Leonard G; HALPERN, Ethan J et al.Radiology. 2005, Vol 237, Num 1, pp 197-201, issn 0033-8419, 5 p.Article

Evaluation of in vitro Dissolution and in vivo Oral Absorption of Dutasteride-Ioaded Eudragit E NanoparticlesKIM, M.-S.Drug research (Stuttgart. 2013. Print). 2013, Vol 63, Num 6, pp 326-330, issn 2194-9379, 5 p.Article

Dutastéride : principaux résultats dans le traitement de l'hypertrophie bénigne de la prostate = Dutasteride: main results in the treatment of the benign prostatic hyperplasiaLE-COENT, R.Annales d'urologie. 2004, Vol 38, pp S62-S66, issn 0003-4401, SUP2Conference Paper

The pharmacokinetic modelling of GII98745 (dutasteride), a compound with parallel linear and nonlinear eliminationGISLESKOG, P. O; HERMANN, D; HAMMARLUND-UDENAES, M et al.British journal of clinical pharmacology. 1999, Vol 47, Num 1, pp 53-58, issn 0306-5251Article

Effet du dutastéride sur la réduction des saignements per-opératoires liés à la résection transuréthrale de prostate = Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostateBOCCON-GIBOD, Laurent; VALTON, Michel; IBRAHIM, Hussein et al.Progrès en urologie (Paris). 2005, Vol 15, Num 6, pp 1085-1089, issn 1166-7087, 5 p.Article

The potent synthetic androgens, dimethandrolone (7α, 11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effectsATTARDI, Barbara J; HILD, Sheri A; KODURI, Sailaja et al.Journal of steroid biochemistry and molecular biology. 2010, Vol 122, Num 4, pp 212-218, issn 0960-0760, 7 p.Article

Formulation and in vivo Evaluation of a Self-Microemulsifying Drug Delivery System of DutasterideCHOO, G.-H; PARK, S.-J; HWANG, S.-J et al.Drug research (Stuttgart. 2013. Print). 2013, Vol 63, Num 4, pp 203-209, issn 2194-9379, 7 p.Article

Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor ― DutasterideLOKE, Y. K; HO, R; SMITH, M et al.Journal of clinical pharmacy and therapeutics (Print). 2013, Vol 38, Num 5, pp 405-415, issn 0269-4727, 11 p.Article

Consequences of Switching 5α-Reductase Inhibitors on Prostate Specific Antigen VelocityHELFAND, Brian T; BLACKWELL, Robert H; MCVARY, Kevin T et al.The Journal of urology. 2010, Vol 184, Num 1, pp 218-223, issn 0022-5347, 6 p.Article

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitorO'LEARY, M. P; ROEHRBORN, C; ANDRIOLE, G et al.BJU international (Papier). 2003, Vol 92, Num 3, pp 262-266, issn 1464-4096, 5 p.Article

Mode of action of human pharmaceuticals in fish: The effects of the 5-alpha-reductase inhibitor, dutasteride, on reproduction as a case studyMARGIOTTA-CASALUCI, Luigi; HANNAH, Robert E; SUMPTER, John P et al.Aquatic toxicology. 2013, Vol 128-129, pp 113-123, issn 0166-445X, 11 p.Article

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitorCLARK, Richard V; HERMANN, David J; CUNNINGHAM, Glenn R et al.The Journal of clinical endocrinology and metabolism. 2004, Vol 89, Num 5, pp 2179-2184, issn 0021-972X, 6 p.Article

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasiaROEHRBORN, Claus G; MARKS, Leonard S; FENTER, Tom et al.Urology (Ridgewood, NJ). 2004, Vol 63, Num 4, pp 709-715, issn 0090-4295, 7 p.Article

ANGIOEDEMA ASSOCIATED WITH DUTASTERIDE THERAPYKAMPITAK, Thatchai; BINKLEY, Karen.Annals of allergy, asthma, & immunology. 2011, Vol 107, Num 4, pp 376-377, issn 1081-1206, 2 p.Article

The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy menAMORY, John K; WANG, Christina; SWERDLOFF, Ronald S et al.The Journal of clinical endocrinology and metabolism. 2007, Vol 92, Num 5, pp 1659-1665, issn 0021-972X, 7 p.Article

Dutastéride pour le traitement de l'hyperplasie bénigne de la prostate = Dutasteride for treatment of benign prostate hyperplasiaThe Medical letter on drugs and therapeutics (Edition française). 2003, Vol 25, Num 2, pp 7-8, issn 0253-8512, 2 p.Article

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostateICZKOWSKI, Kenneth A; JINGXIN QIU; JUNQI QIAN et al.Urology (Ridgewood, NJ). 2005, Vol 65, Num 1, pp 76-82, issn 0090-4295, 7 p.Article

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaROEHRBORN, Claus G; BOYLE, Peter; NICKEL, J. Curtis et al.Urology (Ridgewood, NJ). 2002, Vol 60, Num 3, pp 434-441, issn 0090-4295Article

Mass spectral fragmentation reactions of a therapeutic 4-azasteroid and related compoundsBURINSKY, David J; WILLIAMS, Jon D; THORNQUEST, Alan D et al.Journal of the American Society for Mass Spectrometry. 2001, Vol 12, Num 4, pp 385-398, issn 1044-0305Article

Dutasteride: A new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasiaBROWN, C. T; NUTLALL, M. C.International journal of clinical practice (Esher). 2003, Vol 57, Num 8, pp 705-709, issn 1368-5031, 5 p.Article

Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitorsGISLESKOG, P. O; HERMANN, D; HAMMARLUND-UDENAES, M et al.European journal of pharmaceutical sciences. 1999, Vol 8, Num 4, pp 291-299, issn 0928-0987Article

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE studyMARBERGER, Michael; FREEDLAND, Stephen J; ANDRIOLE, Gerald L et al.BJU international (Papier). 2012, Vol 109, Num 8, pp 1162-1169, issn 1464-4096, 8 p.Article